美国 · SEC FORM 4
Replimune Group, Inc.
REPL · Nasdaq · CIK 0001737953 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
13 同一窗口内观察到的 Form 4 交易行
12 sales · 1 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot.—
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 23,128,025
- 上期报告
- 22,754,597
- 日均成交量
- 2,136,193
- 回补天数
- 10.8
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
本地 Form 4 历史中没有合资格的代码 P 股票买入。
Form 4 申报证据
31 transaction lines in the latest 365-day window; 334 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-20 | Astley-Sparke Philip | 赠与 (G) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-17 | Hill Emily Luisa | 卖出 (S) | Common Stock | 9,256 | USD 14.28 | USD 132,176 | SEC 申报 ↗ |
| 2026-08-10 | Xynos Konstantinos | 卖出 (S) | Common Stock | 11,447 | USD 12.97 | USD 148,468 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-20 | Astley-Sparke Philip | 赠与 (G) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-17 | Hill Emily Luisa | 卖出 (S) | Common Stock | 9,256 | USD 14.28 | USD 132,176 | SEC 申报 ↗ |
| 2026-08-10 | Xynos Konstantinos | 卖出 (S) | Common Stock | 11,447 | USD 12.97 | USD 148,468 | SEC 申报 ↗ |
| 2026-08-10 | Schwendenman Andrew | 卖出 (S) | Common Stock | 7,632 | USD 12.97 | USD 98,987 | SEC 申报 ↗ |
| 2026-08-10 | Patel Sushil | 卖出 (S) | Common Stock | 39,341 | USD 12.97 | USD 510,253 | SEC 申报 ↗ |
| 2026-08-10 | Hill Emily Luisa | 卖出 (S) | Common Stock | 11,448 | USD 12.97 | USD 148,481 | SEC 申报 ↗ |
| 2026-06-01 | Sarchi Christopher | 卖出 (S) | Common Stock | 12,000 | USD 9.24 | USD 110,880 | SEC 申报 ↗ |
| 2026-05-18 | Xynos Konstantinos | 卖出 (S) | Common Stock | 14,023 | USD 5.08 | USD 71,237 | SEC 申报 ↗ |
| 2026-05-18 | Schwendenman Andrew | 卖出 (S) | Common Stock | 7,894 | USD 5.08 | USD 40,102 | SEC 申报 ↗ |
| 2026-05-18 | Sarchi Christopher | 卖出 (S) | Common Stock | 8,626 | USD 5.08 | USD 43,820 | SEC 申报 ↗ |
| 2026-05-18 | Patel Sushil | 卖出 (S) | Common Stock | 37,324 | USD 5.08 | USD 189,606 | SEC 申报 ↗ |
| 2026-05-18 | Hill Emily Luisa | 卖出 (S) | Common Stock | 7,812 | USD 5.08 | USD 39,685 | SEC 申报 ↗ |
| 2026-05-18 | Astley-Sparke Philip | 卖出 (S) | Common Stock | 17,657 | USD 5.08 | USD 89,698 | SEC 申报 ↗ |
| 2026-04-02 | Sarchi Christopher | 卖出 (S) | Common Stock | 6,500 | USD 8.01 | USD 52,065 | SEC 申报 ↗ |
| 2026-04-01 | Xynos Konstantinos | 奖励／授予 (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-01 | Schwendenman Andrew | 奖励／授予 (A) | Common Stock | 36,667 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-01 | Sarchi Christopher | 奖励／授予 (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-01 | Patel Sushil | 奖励／授予 (A) | Common Stock | 251,240 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-01 | Hill Emily Luisa | 奖励／授予 (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-01 | Astley-Sparke Philip | 奖励／授予 (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-18 | Astley-Sparke Philip | 赠与 (G) | Common Stock | 25,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-19 | Xynos Konstantinos | 奖励／授予 (A) | Common Stock | 60,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-19 | Schwendenman Andrew | 奖励／授予 (A) | Common Stock | 10,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-19 | Sarchi Christopher | 奖励／授予 (A) | Common Stock | 35,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-19 | Patel Sushil | 奖励／授予 (A) | Common Stock | 200,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-19 | Hill Emily Luisa | 奖励／授予 (A) | Common Stock | 60,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-09 | Dhingra Kapil | 卖出 (S) | Common Stock | 3,169 | USD 10.40 | USD 32,958 | SEC 申报 ↗ |
| 2025-12-09 | Dhingra Kapil | 期权行权／转换 (M) | Common Stock | 3,169 | USD 1.75 | USD 5,546 | SEC 申报 ↗ |
| 2025-12-02 | Patel Sushil | 卖出 (S) | Common Stock | 10,000 | USD 11.13 | USD 111,300 | SEC 申报 ↗ |
| 2025-11-17 | Xynos Konstantinos | 卖出 (S) | Common Stock | 7,248 | USD 9.10 | USD 65,957 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | REPL |
| CIK | 0001737953 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 334 transaction lines from 2020-02-12 to 2026-08-20 0 P purchase lines · 252 S sale lines · 82 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.